Argenx stock (NL0010832176): FDA Expands Vyvgart Label for Generalized Myasthenia Gravis

Argenx secured U.S. FDA approval on May 8 to expand Vyvgart and Vyvgart Hytrulo for all adult patients with generalized myasthenia gravis, significantly broadening the eligible patient population for its lead immunology treatment.

Argenx SE announced a significant regulatory milestone on May 8, 2026, when the U.S. Food and Drug Administration approved a label expansion for VYVGART® (efgartigimod alfa-fcab) and VYVGART Hytrulo® (efgartigimod alfa and hyaluronidase-qvfc) to treat all adult patients with generalized myasthenia gravis (gMG), according to BioSpace as of May 8, 2026. This approval removes previous serotype restrictions, allowing the company to reach a substantially larger patient population in the United States.

As of: 11.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Argenx SE
• Sector/industry: Biotechnology / Immunology
• Headquarters/country: Amsterdam, Netherlands
• Core markets: United States, Japan, China, Europe
• Key revenue drivers: VYVGART (neonatal Fc receptor blocker for autoimmune diseases)
• Home exchange/listing venue: Nasdaq (ARGX), Euronext Brussels (ARGX)
• Trading currency: USD (Nasdaq), EUR (Euronext)

Argenx: core business model

Argenx is a global immunology company focused on developing and commercializing therapies for severe autoimmune diseases. The company pioneered the first approved neonatal Fc receptor (FcRn) blocker, a mechanism that addresses underlying immune dysfunction by reducing pathogenic antibodies. VYVGART represents the company's flagship asset and is being evaluated across multiple serious autoimmune indications beyond its initial gMG approval, positioning Argenx as a science-driven biotech with a differentiated therapeutic approach.

Main revenue and product drivers for Argenx

VYVGART and VYVGART Hytrulo are the primary commercial drivers for Argenx. The May 8 FDA label expansion removes serotype restrictions for gMG, meaning the treatment can now be prescribed to all eligible adult patients rather than only those with specific antibody profiles. This broadens the addressable market significantly and reduces prescribing complexity for physicians. The company is also advancing earlier-stage experimental medicines within its therapeutic franchises, with potential applications across dozens of severe autoimmune diseases, creating a pipeline-driven growth narrative for US investors.

Analyst sentiment and market reaction

Following the FDA approval announcement, multiple Wall Street banks reaffirmed or upgraded their positions on Argenx. Deutsche Bank, Jefferies, and Goldman Sachs maintained or issued Buy ratings, according to MarketScreener as of May 8, 2026, while UBS remained Neutral. HC Wainwright increased its Q4 2026 earnings per share estimates for Argenx to $7.00 per share on May 8, reflecting analyst confidence in the commercial impact of the label expansion.

Why Argenx matters for US investors

Argenx trades on Nasdaq under the ticker ARGX, making it directly accessible to US retail and institutional investors. The company's lead product addresses a significant unmet need in the US autoimmune disease market, where gMG affects thousands of patients. The FDA label expansion removes a key commercial barrier and positions Argenx to capture a larger share of the US immunology market, a sector with strong pricing power and recurring revenue potential. For growth-oriented biotech investors, Argenx represents exposure to a differentiated mechanism with multi-indication potential.

Conclusion

The May 8 FDA approval for VYVGART label expansion marks a meaningful de-risking event for Argenx, removing serotype restrictions and broadening the eligible patient population for its lead immunology asset. Analyst support and the company's pipeline of earlier-stage candidates suggest continued momentum. US investors should monitor upcoming commercial uptake data and pipeline progress as key catalysts for the stock.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.